BIO Asia–Taiwan 2025 亞洲生技大會

BIO Asia–Taiwan 2025 亞洲生技大會

≡

論壇議程總覽

2025 Plenary Sessions Agenda

​​

Date Wed., July 23, 2025

Venue Room 701AB, 7F, TaiNEX2

09:00 – 10:30

Plenary Session 1 – Global Biotech Development

The imposition of import tariffs and their effects on global trade are threatening to upend essential cross-border supply chains that the biomedical industries are built on. Plenary Session 1 gathers biotech leaders from Asia and around the world to discuss this and other topics important to the industry, including Taiwan's role in today's biotech industry; the current state of international collaborations; and the biotech industry's strategic importance, both now and in the future. The highlight of the session will be the Tang Prize Lecture featuring Jens Juul Holst and spotlighting his groundbreaking work on GLP-1, a discovery transforming diabetes treatment and metabolic health worldwide. 
09:00 – 09:05

Conference Opening

Welcoming Remarks

  • Johnsee Lee, Chairman of BIO Asia–Taiwan 2025; Honorary Chairman, Taiwan Bio Industry Organization (Taiwan BIO)
  • Lee-Cheng Liu, Chairman, Taiwan Bio Industry Organization
09:05– 09:10

Session Chair

  • Lee-Cheng Liu, Chairman, Taiwan Bio Industry Organization

Greetings from BIO

  • Kelly Seagraves, Vice President for National Security and International Affairs, Biotechnology Innovation Organization (BIO)
09:10– 09:30

BIO Asia Award Lecture
To Build Well-educated, Healthy Middle Class by Establishing Technology Industry

09:30– 09:50

Topic TBD

09:50 – 10:10

Topic TBD

10:10 – 10:30

Tang Prize Lecture

Topic (GLP-1 Discovery & Development)

  • Jens Juul Holst, Tang Prize Laureate; Professor, University of Copenhagen

10:30 – 11:50

Plenary Session 2 – Global Biotech Development

Continuing with the themes of Session 1, Plenary Session 2 highlights transformative biotech strategies shaping the Asia-Pacific region and beyond. Discussions will cover how to advance regional innovation and patient access; how genomics is redefining the future of healthcare and life sciences investment, as well as other highly-pertinent topics. The session promises dialogue at the intersection of science, policy, and business, providing a forward-facing perspective on biotech’s evolving impact and global potential.
10:30 – 10:50

Formosalab 30th Anniversary Lecture
Topic TBD

  • Manuel Sanz, COO, Oncomatryx Biopharma
10:50 – 11:10

Topic TBD

  • David Flores, Co-Founder, President & CEO, BioCentury
11:10 – 11:30

From Science Fiction to Reality: Capitalising on the Genomic Revolution

11:30 – 11:50

Topic TBD

  • Syneos Health

12:00 – 13:20

Plenary Session 3 – The Value of Innovation for a Healthier Taiwan

Plenary Session 3 is Taiwan-focused, and will explore how innovation drives public health and sustainable growth on the island. The session will emphasize Taiwan’s strategic role in the life sciences ecosystem, highlighting policy frameworks fostering innovation and accessibility. Thought leaders from the pharmaceutical, biotech, and healthcare sectors will examine the current state of local R&D, current levels of digital transformation in Taiwan, and recent cross-sector collaboration. Discussion will also delve into aligning innovation with healthcare equity and long-term societal value. This session reinforces the critical link between scientific advancement and a healthier, more resilient Taiwan.
12:00 – 12:10

Opening Remarks

  • Johnsee Lee, Chairman of BIO Asia–Taiwan 2025
  • Grant Hu, President of IRPMA, CEO & President of Eisai Taiwan
12:10 – 12:25

Always Innovating: Pharmaceutical Industry Facts and Figures (TBD)

David Reddy, Director General, IFPMA (TBC)

12:25 – 12:40

Why the Innovation Important to Patients? The Value of Cell and Gene Therapy (TBC)

Stephen Moran, Novartis R&D

12:40 – 12:55

Partnership for Prevention: Getting Ahead of Diseases with Innovation to Advance a Healthier Future

Tina Graves, VP and General Manager, GSK Taiwan

12:55 – 13:15

Panel Discussion

Moderator:

  • Johnsee Lee, Chairman of BIO Asia–Taiwan 2025 (TBC)

Panelist:

  • Luke BI, Executive Director, Head of China BioA and APAC LCMS, Labcorp
  • Three speakers (Tina Graves, David Reddy(TBC), speaker from Novartis(TBC))
13:15 – 13:20

Closing Remarks

  • Grant Hu, President of IRPMA, CEO & President of Eisai Taiwan